Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor

被引：0
|
作者：
Dong-Hoe Koo
Min-Hee Ryu
Baek-Yeol Ryoo
Mo Youl Beck
Young-Soon Na
Jae-Gook Shin
Sang Seop Lee
Eun-Young Kim
Yoon-Koo Kang
机构：
[1] Asan Medical Center,Department of Oncology, University of Ulsan College of Medicine
[2] Asan Medical Center,Asan Institute for Life Science
[3] Inje University College of Medicine,Department of Pharmacology and Pharmacogenomics Research Center
[4] Inje University Busan Paik Hospital,Department of Clinical Pharmacology
[5] Sungkyunkwan University School of Medicine,Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Gastrointestinal stromal tumor; Imatinib; Single-nucleotide polymorphism; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：173 / 182
页数：9
相关论文
共 50 条
  • [1] Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor
    Koo, Dong-Hoe
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Beck, Mo Youl
    Na, Young-Soon
    Shin, Jae-Gook
    Lee, Sang Seop
    Kim, Eun-Young
    Kang, Yoon-Koo
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 173 - 182
  • [2] Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
    Koo, Dong Hoe
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Beck, Mo Youl
    Na, Young-Soon
    Shin, Jae-Gook
    Lee, Sang Seop
    Kim, Eun-Young
    Kang, Yoon-Koo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors
    Michiel C. Verboom
    Jacqueline S. L. Kloth
    Jesse J. Swen
    Stefan Sleijfer
    Anna K. L. Reyners
    Neeltje Steeghs
    Ron H. J. Mathijssen
    Hans Gelderblom
    Henk-Jan Guchelaar
    [J]. The Pharmacogenomics Journal, 2019, 19 : 473 - 479
  • [4] Clinical Efficacy and Safety of Sunitinib After Imatinib Failure in Japanese Patients with Gastrointestinal Stromal Tumor
    Matsumoto, Kazuya
    Sawaki, Akira
    Mizuno, Nobumasa
    Hara, Kazuo
    Hijioka, Susumu
    Niwa, Yasumasa
    Tajika, Masahiro
    Kawai, Hiroki
    Kondo, Shinya
    Yamao, Kenji
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (01) : 57 - 62
  • [5] Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients
    Li, Jian
    Gong, Ji-Fang
    Li, Jie
    Gao, Jing
    Sun, Nai-Ping
    Shen, Lin
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (07) : 698 - 703
  • [6] Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients
    Jian Li
    [J]. World Journal of Gastroenterology, 2012, (07) : 698 - 703
  • [7] Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors
    Verboom, Michiel C.
    Kloth, Jacqueline S. L.
    Swen, Jesse J.
    Sleijfer, Stefan
    Reyners, Anna K. L.
    Steeghs, Neeltje
    Mathijssen, Ron H. J.
    Gelderblom, Hans
    Guchelaar, Henk-Jan
    [J]. PHARMACOGENOMICS JOURNAL, 2019, 19 (05): : 473 - 479
  • [8] ASSOCIATION OF ABCG2 POLYMORPHISM WITH PLASMA CONCENTRATIONS OF AXITINIB IN PATIENTS WITH RENAL CELL CARCINOMA
    Kato, Hiroshi
    Miyazaki, Masayuki
    Takeuchi, Mio
    Sassa, Naoto
    Nagai, Taku
    Noda, Yukihiro
    Yamada, Kiyofumi
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [9] EVALUATION OF GASTROINTESTINAL STROMAL TUMOR PATIENTS AND IMATINIB THERAPY
    Dincer, S.
    Akboru, H.
    Teke, F.
    Eren, B.
    Askaroglu, B.
    Demir, C.
    Aykanat, A.
    Unsal, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 270 - 271
  • [10] Imatinib and ABCG2: who controls whom?
    Melo, Junia V.
    [J]. BLOOD, 2006, 108 (04) : 1116 - 1117
12345